Silexion Reports New Preclinical Findings For SIL-204; Latest Preclinical Studies Reveal Significant Improvements In Stability, Efficacy, And KRAS Targeting Range For Next-generation SiRNA Candidate SIL-204
Silexion Reports New Preclinical Findings For SIL-204; Latest Preclinical Studies Reveal Significant Improvements In Stability, Efficacy, And KRAS Targeting Range For Next-generation SiRNA Candidate SIL-204
Silexion针对SIL-204报告了新的临床前发现；最新的临床前研究显示，下一代SiRNA候选药物SIL-204的稳定性、功效和KRAS靶向范围有显著改善。
These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis of the human pancreatic cell line that bears the KRAS G12D mutation xenotransplanted into mice. Given that this mutation constitutes the largest segment of pancreatic cancer subtypes, it represents a significant in the development of SIL-204.
这些最新发现表明，最新的SIL-204微粒配方能够抑制携带KRAS G12D突变的人类胰腺细胞系在小鼠体内异种移植后的生长，并诱导坏死。考虑到这种突变占据了胰腺癌亚型中最大的部分，这对SIL-204的开发具有重要意义。